These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 34688627)

  • 1. Luteolin alleviates ischemia/reperfusion injury-induced no-reflow by regulating Wnt/β-catenin signaling in rats.
    Qin X; Qin H; Li Z; Xue S; Huang B; Liu X; Wang D
    Microvasc Res; 2022 Jan; 139():104266. PubMed ID: 34688627
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tongmai Yangxin pill reduces myocardial no-reflow by regulating apoptosis and activating PI3K/Akt/eNOS pathway.
    Chen R; Chen T; Wang T; Dai X; Meng K; Zhang S; Jiang D; Wang Y; Zhou K; Geng T; Xu J; Wang Y
    J Ethnopharmacol; 2020 Oct; 261():113069. PubMed ID: 32619593
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SHP-1/STAT3 Interaction Is Related to Luteolin-Induced Myocardial Ischemia Protection.
    Liu D; Luo H; Qiao C
    Inflammation; 2022 Feb; 45(1):88-99. PubMed ID: 34460026
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The protective effect of Luteolin on myocardial ischemia/reperfusion (I/R) injury through TLR4/NF-κB/NLRP3 inflammasome pathway.
    Zhang X; Du Q; Yang Y; Wang J; Dou S; Liu C; Duan J
    Biomed Pharmacother; 2017 Jul; 91():1042-1052. PubMed ID: 28525945
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reduction of no-reflow and reperfusion injury with the synthetic 17β-aminoestrogen compound Prolame is associated with PI3K/Akt/eNOS signaling cascade.
    Hernández-Reséndiz S; Palma-Flores C; De Los Santos S; Román-Anguiano NG; Flores M; de la Peña A; Flores PL; Fernández-G JM; Coral-Vázquez RM; Zazueta C
    Basic Res Cardiol; 2015 Mar; 110(2):1. PubMed ID: 25589055
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanism and potential treatment of the "no reflow" phenomenon after acute myocardial infarction: role of pericytes and GPR39.
    Methner C; Cao Z; Mishra A; Kaul S
    Am J Physiol Heart Circ Physiol; 2021 Dec; 321(6):H1030-H1041. PubMed ID: 34623177
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Shenlian extract decreases mitochondrial autophagy to regulate mitochondrial function in microvascular to alleviate coronary artery no-reflow.
    Li JJ; Wang YJ; Wang CM; Li YJ; Yang Q; Cai WY; Chen Y; Zhu XX
    Phytother Res; 2023 May; 37(5):1864-1882. PubMed ID: 36740450
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antioxidative effect of luteolin pretreatment on simulated ischemia/reperfusion injury in cardiomyocyte and perfused rat heart.
    Zhang RQ; Li DY; Xu TD; Zhu SS; Pan HJ; Fang F; Wu X; Sun H
    Chin J Integr Med; 2017 Jul; 23(7):518-527. PubMed ID: 26956461
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Luteolin Inhibits Ischemia/Reperfusion-Induced Myocardial Injury in Rats via Downregulation of microRNA-208b-3p.
    Bian C; Xu T; Zhu H; Pan D; Liu Y; Luo Y; Wu P; Li D
    PLoS One; 2015; 10(12):e0144877. PubMed ID: 26658785
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Baicalein and luteolin inhibit ischemia/reperfusion-induced ferroptosis in rat cardiomyocytes.
    Wang IC; Lin JH; Lee WS; Liu CH; Lin TY; Yang KT
    Int J Cardiol; 2023 Mar; 375():74-86. PubMed ID: 36513286
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Luteolin inhibits ROS-activated MAPK pathway in myocardial ischemia/reperfusion injury.
    Yu D; Li M; Tian Y; Liu J; Shang J
    Life Sci; 2015 Feb; 122():15-25. PubMed ID: 25476833
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tongmai Yangxin pill reduces myocardial No-reflow via endothelium-dependent NO-cGMP signaling by activation of the cAMP/PKA pathway.
    Chen R; Chen T; Wang T; Dai X; Zhang S; Jiang D; Meng K; Wang Y; Geng T; Xu J; Zhou K; Wang Y
    J Ethnopharmacol; 2021 Mar; 267():113462. PubMed ID: 33058924
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Delayed therapeutic hypothermia protects against the myocardial no-reflow phenomenon independently of myocardial infarct size in a rat ischemia/reperfusion model.
    Dai W; Hale S; Kloner RA
    Int J Cardiol; 2017 Jun; 236():400-404. PubMed ID: 28108128
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Coronary Endothelium No-Reflow Injury Is Associated with ROS-Modified Mitochondrial Fission through the JNK-Drp1 Signaling Pathway.
    Chen Y; Liu C; Zhou P; Li J; Zhao X; Wang Y; Chen R; Song L; Zhao H; Yan H
    Oxid Med Cell Longev; 2021; 2021():6699516. PubMed ID: 33613824
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hydrogen gas inhalation alleviates myocardial ischemia-reperfusion injury by the inhibition of oxidative stress and NLRP3-mediated pyroptosis in rats.
    Nie C; Ding X; A R; Zheng M; Li Z; Pan S; Yang W
    Life Sci; 2021 May; 272():119248. PubMed ID: 33621592
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of miR-148b ameliorates myocardial ischemia/reperfusion injury via regulation of Wnt/β-catenin signaling pathway.
    Yang M; Kong DY; Chen JC
    J Cell Physiol; 2019 Aug; 234(10):17757-17766. PubMed ID: 30820984
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Postconditioning fails to improve no reflow or alter infarct size in an open-chest rabbit model of myocardial ischemia-reperfusion.
    Hale SL; Mehra A; Leeka J; Kloner RA
    Am J Physiol Heart Circ Physiol; 2008 Jan; 294(1):H421-5. PubMed ID: 17993599
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sodium tanshinone IIA sulfonate ameliorates experimental coronary no-reflow phenomenon through down-regulation of FGL2.
    Long R; You Y; Li W; Jin N; Huang S; Li T; Liu K; Wang Z
    Life Sci; 2015 Dec; 142():8-18. PubMed ID: 26482204
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Luteolin Modulates SERCA2a Leading to Attenuation of Myocardial Ischemia/ Reperfusion Injury via Sumoylation at Lysine 585 in Mice.
    Du Y; Liu P; Xu T; Pan D; Zhu H; Zhai N; Zhang Y; Li D
    Cell Physiol Biochem; 2018; 45(3):883-898. PubMed ID: 29421780
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New strategies for the management of no-reflow after primary percutaneous coronary intervention.
    Niccoli G; Cosentino N; Spaziani C; Minelli S; Fracassi F; Crea F
    Expert Rev Cardiovasc Ther; 2011 May; 9(5):615-30. PubMed ID: 21615325
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.